While Capitol Hill goes back on forth on drug pricing legislation, states are looking to test their own solutions this year.
According to a STAT report, Louisiana and Washington both are looking to deploy a subscription-based payment model for hepatitis C treatments. As part of the agreement, states would pay drugmakers a flat rate for an unlimited supply of the drugs.
Colorado is also taking a big leap on insulin prices after capping the cost of the drug at $100 for the state’s insured.
To read the full report on STAT, click here. (Paid subscription required)